The value of MRD in multiple myeloma

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses the value of minimal residual disease (MRD) in multiple myeloma (MM).

In this video, Prof. Mohty discusses the use of MRD status in the treatment of patients with MM, highlighting an abstract presented by Luciano Costa during the ASH meeting, that showed it is feasible to use MRD-status to drive therapeutic decisions. However, it is important to note this trial was not a prospective randomized phase III trial. Prof. Mothy also notes the value of PET scanning as demonstrated in the CASSIOPET trial, and that MRD testing cannot replace PET scanning, rather they are complimentary. Lastly, Prof. Mohty comments on the potential use of mass spectrometry to test MRD-status, removing the requirement for bone marrow sample and giving very precise information.